HC Wainwright Increases Earnings Estimates for Scholar Rock

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for Scholar Rock in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.69) for the quarter, up from their prior estimate of ($0.72). The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock's Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.73) EPS, FY2026 earnings at ($1.96) EPS, FY2027 earnings at ($1.15) EPS and FY2028 earnings at ($0.12) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter in the previous year, the business posted ($0.59) earnings per share.

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Trading Down 1.5%

Shares of NASDAQ SRRK traded down $0.46 during midday trading on Monday, hitting $30.00. The stock had a trading volume of 825,200 shares, compared to its average volume of 1,267,164. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of -12.77 and a beta of 0.37. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average price of $30.77 and a 200 day moving average price of $35.94.

Insiders Place Their Bets

In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the transaction, the chief financial officer now owns 111,345 shares in the company, valued at $3,966,108.90. The trade was a 56.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tracey Sacco sold 5,000 shares of the business's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $32.83, for a total value of $164,150.00. Following the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,355,552.50. This trade represents a 6.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,798 shares of company stock worth $5,482,238 over the last quarter. 13.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SRRK. Intech Investment Management LLC lifted its holdings in Scholar Rock by 60.9% in the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company's stock worth $1,826,000 after buying an additional 21,483 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock worth $5,460,000 after acquiring an additional 34,594 shares in the last quarter. Exome Asset Management LLC lifted its stake in shares of Scholar Rock by 8.9% in the first quarter. Exome Asset Management LLC now owns 84,339 shares of the company's stock worth $2,711,000 after acquiring an additional 6,900 shares in the last quarter. Jones Financial Companies Lllp acquired a new position in shares of Scholar Rock in the first quarter worth about $1,159,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Scholar Rock in the first quarter worth about $458,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.